Banner for news page 720

September 2020

15 September

Chiesi validates the power of Bioasis technology to propel drugs across the blood-brain barrier (BBB). Scientists at Bioasis Technologies Inc have worked for over a decade to develop a technology – the patented xB3 platform – which helps small molecules shuttle across the BBB safely. The xB3 platform is a very versatile, high capacity delivery system able to deliver antibodies, enzymes, siRNA as well as small molecules across the BBB. 

https://www.proactiveinvestors.com/companies/news/929031/bioasis-on-a-roll-after-chiesi-validates-the-power-of-its-technology-to-propel-drugs-across-the-blood-brain-barrier-929031.html

 

14 September

CarThera, a French company that designs and develops innovative ultrasound-based medical devices to treat brain disorders, today announces that it has been selected by the EIC Accelerator Pilot to receive a €2 million ($2.3M) grant and €10.5M ($12M) in equity for the development of its DOMEUS project for the treatment of glioblastoma (GBM) patients.

https://www.pharmiweb.com/press-release/2020-09-14/carthera-to-receive-2m-grant-and-105m-equity-from-the-european-innovation-council-for-development

 

3 September

A novel drug delivery system by the global engineering technologies company, Renishaw, was successfully used as part of an extension study to a first-in-human clinical trial for the treatment of Parkinson’s disease. As one of the novel infusion regimes, neuroinfuse is currently only used in approved clinical trial settings. In order to eventually make the device generally available to patients, Renishaw is seeking academic, clinical, and industrial partners across a wide range of indications, from oncology to neurodegenerative diseases.

https://3dprint.com/272414/3d-printed-drug-delivery-implant-achieves-successful-clinical-trial-for-parkinsons-disease/